Triple-negative breast cancer accounts for approximately 20% of breast cancer cases worldwide. Its hallmark is the absence of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2). This receptor-negative status precludes the use of hormonal or HER2-targeted treatments, severely limiting therapeutic options. Clinically, TNBC disproportionately affects younger women, exhibits rapid metastatic potential, and is burdened by a high rate of early recurrence and mortality. These aggressive characteristics have positioned TNBC as a critical challenge in oncology.

Given the lack of conventional molecular targets in TNBC, research efforts have expanded beyond the malignant cells to encompass their surrounding environment. The tumour microenvironment comprises a dynamic consortium of connective tissue, immune cells, fibroblasts, extracellular matrix components, and vasculature. This environment can paradoxically either impede or foster tumorigenesis, suggesting that its molecular interplay may hold keys to combating the disease.

In an innovative study published in Current Drug Therapy, a multidisciplinary team at the HSE Faculty of Biology and Biotechnology dissected the gene expression profiles of both TNBC tumour cells and their microenvironment components. By correlating these molecular data with extensive patient clinical records, they identified critical regulatory pathways influencing tumour aggressiveness and patient outcomes. Central to their discovery is the insulin-like growth factor 2 (IGF2), a well-known signalling protein implicated in tissue growth and repair, but hijacked in cancer to fuel unregulated proliferation.

Contrary to conventional assumptions that the tumour cells produce the essential growth-supporting factors, this study found that fibroblasts—connective tissue cells resident within the tumour microenvironment—are the predominant source of IGF2 in TNBC. These fibroblasts, normally maintaining tissue architecture and homeostasis, seem to switch roles under the pathological state, becoming facilitators of cancer progression by secreting IGF2, effectively “fueling the fire” of tumour expansion.

Adjacent to this growth-promoting mechanism, the tumour possesses an intrinsic regulatory system aimed at tempering unchecked development. This restraint is mediated by the insulin-like growth factor binding protein 6 (IGFBP6), a molecular “trap” that binds IGF2, preventing it from excessive activation of tumour cells. Intriguingly, the researchers observed that both tumour and microenvironmental cells produce IGFBP6 as a counterbalance to growth stimuli, suggesting a finely tuned equilibrium under normal conditions.

The study’s clinical analysis revealed a troubling link between diminished IGFBP6 expression and heightened infiltration of macrophages within tumours. Macrophages, pivotal immune cells tasked with host defense, can undergo functional reprogramming in cancer to adopt tumor-supportive roles. This reprogramming fosters a pro-tumoral milieu, promoting angiogenesis, matrix remodeling, and immune suppression, factors collectively contributing to accelerated disease recurrence and poor prognosis in affected patients.

These findings carry immediate translational significance. Measuring IGFBP6 levels in tumour biopsies could serve as a prognostic biomarker, enabling clinicians to stratify patients by recurrence risk more accurately. High-risk individuals with low IGFBP6 expression and macrophage-enriched tumours might benefit from intensified surveillance and tailored therapeutic regimens, potentially improving survival outcomes.

Looking forward, the elucidation of this tumour microenvironment axis opens exciting prospects for the development of novel treatments. Current chemotherapeutic strategies targeting rapidly dividing cancer cells often fall short against TNBC’s resilience. Redirecting therapeutic focus to the supportive fibroblasts and immune components within the microenvironment offers a promising paradigm shift. For instance, elevating IGFBP6 levels pharmacologically or inhibiting IGF2 production in fibroblasts could undermine the tumour’s growth advantage, effectively “starving” cancer cells of their supportive niche.

Maxim Shkurnikov, leading the research at HSE’s Laboratory for Research on Molecular Mechanisms of Longevity, emphasizes this strategic reorientation: “Conventional chemotherapy primarily targets rapidly dividing cells, and in triple-negative breast cancer this is often insufficient. We propose shifting the focus to the tumour microenvironment and targeting the cells that support tumour growth. By modulating IGFBP6 and IGF2 dynamics, we hope to develop therapies that significantly reduce the risk of rapid recurrence.”

This research underscores the critical importance of the tumour microenvironment in dictating cancer progression and recurrence, particularly in TNBC, where options remain limited. It aligns with a growing body of evidence suggesting that addressing not only the malignant cells but also the surrounding stromal and immune components is essential for durable therapeutic success.

Moreover, this discovery may have implications beyond TNBC, offering insights into other malignancies where the IGF axis and immune microenvironment interplay governs tumour behavior. The identification of biomarkers like IGFBP6 and the delineation of fibroblast-derived IGF2 in cancer progression herald a new wave of personalized oncology approaches grounded in microenvironmental biology.

In summary, the HSE University study marks a significant advance in cancer biology, highlighting that the aggressive nature of triple-negative breast cancer is not solely an intrinsic feature of tumour cells but critically influenced by their microenvironment. By targeting these auxiliary cells and their molecular signals, there lies an opportunity to outmaneuver this formidable disease and improve outcomes for patients currently facing limited options.

Subject of Research: Molecular mechanisms and tumour microenvironment in triple-negative breast cancer

Article Title: IGFBP6 Expression Correlates with Macrophage Presence in Triple-Negative Breast Cancer Tumors

News Publication Date: 2 January 2026

Web References:
https://doi.org/10.2174/0115748855416908251120055038

References:
HSE University research team, Current Drug Therapy, 2026

Keywords:
Triple-negative breast cancer, tumour microenvironment, IGF2, IGFBP6, fibroblasts, macrophages, cancer recurrence, molecular oncology, tumour progression, targeted therapy, immune cells, cancer biomarkers

Epigenetics, which refers to heritable changes in gene expression that do not involve alterations in the DNA sequence itself, plays a pivotal role in cellular behavior, particularly in cancer biology and immune regulation. This study dives deep into how the epigenetic remodeling of mast cells—the body’s frontline defenders—and cancer cells collectively modulates the biochemical signaling networks that favor tumor progression. By decoding these modifications, the research offers a fresh perspective on the tumor microenvironment, an ecosystem critical to cancer development and metastasis.

Mast cells have traditionally been recognized for their role in allergic reactions and host defense; however, their involvement in tumor biology has gained significant traction in recent years. These versatile immune cells secrete a spectrum of cytokines and proteases, influencing inflammation and the immune milieu. Intriguingly, the study reveals that epigenetic changes in mast cells can drastically shift their cytokine secretion profiles, transforming them from fighters against pathogens into inadvertent accomplices in cancer growth. This duality presents a fascinating biological paradox and spotlights mast cells as potential epigenetic targets in oncology.

The crux of the investigation centers on how cancer cells manipulate their own epigenetic states alongside those of nearby mast cells to orchestrate a tumor-promoting environment. The researchers employed state-of-the-art genome-wide epigenomic profiling techniques, such as chromatin immunoprecipitation sequencing (ChIP-seq) and DNA methylation mapping, to delineate modifications in histone marks and DNA methylation patterns. These epigenetic marks collectively influence gene activation and repression, thereby modulating cytokine gene expression crucial for tumor-immune interactions.

One of the key findings of this study is the identification of a specific epigenetic signature that underpins the aberrant cytokine production in both mast and cancer cells. This signature comprises hypomethylated promoter regions in genes encoding pro-tumorigenic cytokines like interleukin-6 (IL-6), tumor necrosis factor-alpha (TNF-α), and transforming growth factor-beta (TGF-β). These changes promote an inflammatory milieu conducive to tumor immune evasion, angiogenesis, and extracellular matrix remodeling—all hallmarks of cancer progression.

Importantly, the research highlights the bidirectional nature of epigenetic reprogramming in the tumor microenvironment. Not only do cancer cells induce epigenetic alterations in mast cells via paracrine signaling and extracellular vesicles, but mast cells also reciprocally influence the epigenetic landscape of cancer cells. This crosstalk leads to a feed-forward loop of cytokine production that exacerbates tumor aggressiveness and resistance to therapy.

Delving further into the mechanistic details, the team uncovered that key epigenetic regulators, including DNA methyltransferases (DNMTs) and histone deacetylases (HDACs), are involved in setting and maintaining these pro-tumoral epigenetic states. Pharmacological inhibition of these enzymes in experimental models was sufficient to reverse the aberrant cytokine profiles, reducing tumor growth and metastatic potential. These insights offer tantalizing prospects for epigenetic therapy strategies aimed at reprogramming the tumor microenvironment.

Another layer of complexity is added by the discovery that non-coding RNAs, particularly microRNAs (miRNAs) and long non-coding RNAs (lncRNAs), serve as critical epigenetic modulators in this context. These molecules fine-tune gene expression post-transcriptionally, with some aberrantly expressed in mast and cancer cells, further fueling the tumor-promoting cytokine networks. The integration of non-coding RNA regulation with classical epigenetic modifications presents a holistic view of gene regulatory networks in cancer immunobiology.

The translational implications of this study are profound. By targeting the epigenetic machinery that governs mast cell and cancer cell interactions, it may be possible to dismantle the supportive tumor niche and enhance the efficacy of existing immunotherapies. Current immune checkpoint inhibitors have revolutionized cancer treatment but face limitations due to the immunosuppressive microenvironment. Modulating epigenetic programs in these influential cells could sensitize tumors to immune attack and prevent relapse.

Furthermore, this research challenges the traditional notion of mast cells solely as inflammatory effectors, positioning them squarely within the epigenetic landscape of cancer immunology. It paves the way for the development of novel biomarkers based on epigenetic and cytokine signatures that could predict tumor behavior and patient prognosis. Detecting these molecular fingerprints in patient samples might allow for personalized therapeutic approaches that consider both tumor and immune components.

The holistic understanding of tumor-promoting cytokine networks provided by this epigenetic lens also extends beyond oncology. Chronic inflammatory diseases, autoimmune disorders, and even infectious diseases could be re-examined through the paradigm of immune cell reprogramming. This study thus not only deepens our grasp of cancer pathology but also enriches the broader field of immunology with refined mechanistic insights.

Critically, the authors underscore the need for further research into the temporal dynamics of epigenetic reprogramming. Tumor progression is a multistage process where the immune microenvironment evolves constantly. Longitudinal analyses and single-cell epigenomic profiling stand out as promising approaches to unravel the stepwise changes in mast cells and cancer cells, potentially uncovering windows of opportunity for therapeutic intervention.

Moreover, the study’s comprehensive methodological approach involving in vitro cell culture systems, animal models, and patient-derived tumor samples strengthens the validity of the findings and their relevance to human disease. By bridging experimental models with clinical observations, the research provides a robust framework for translating epigenetic insights into tangible clinical benefits.

The implications of epigenetic reprogramming in tumor-promoting cytokine networks are equally significant in light of tumor heterogeneity. Different cancer types and even subpopulations within a tumor may exhibit distinct epigenetic patterns governing cytokine production. Personalized epigenetic profiling could thus become an integral part of precision oncology, tailoring interventions to the unique epigenomic landscape of each patient’s tumor.

In sum, this seminal work not only uncovers the intricate layers of epigenetic regulation that drive mast cell and cancer cell-mediated tumor promotion but also charts a promising course toward innovative therapeutic paradigms. The convergence of epigenetics, immunology, and oncology heralds a new era in cancer research with the potential to transform patient outcomes and circumvent the formidable barriers posed by tumor microenvironmental complexity.

As the scientific community continues to unravel the epigenetic choreography of cellular actors within tumors, studies like this exemplify the power of integrative research to pave the way for next-generation cancer treatments. With precision epigenetic interventions on the horizon, the prospect of shifting the balance from tumor promotion to tumor eradication becomes not just conceivable but imminent.

Subject of Research: Epigenetic reprogramming of mast cells and cancer cells and its impact on tumor-promoting cytokine networks.

Article Title: Epigenetic reprogramming of mast and cancer cells modifies tumor-promoting cytokine networks.

Article References:
Schcolnik-Cabrera, A., Ramírez-Yautentzi, M., Soria-Castro, R. et al. Epigenetic reprogramming of mast and cancer cells modifies tumor-promoting cytokine networks. Med Oncol 42, 371 (2025). https://doi.org/10.1007/s12032-025-02941-9

Image Credits: AI Generated